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Abstract
The principal objective of this study was to evaluate the chemopreventive and therapeutic effects of a combination of all-trans-retinoic acid (RA)
and knockdown of delta-like 1 homologue (Drosophila) (DLK1) on neuroblastoma, the most common malignant disease in children. As unfavorable
neuroblastoma is poorly differentiated, neuroblastoma cell was induced differentiation by RA or DLK1 knockdown. Neuroblastoma cells showed
elongated neurite growth, a hallmark of neuronal differentiation at various doses of RA, as well as by DLK1 knockdown. In order to determine 
whether or not a combination of RA and DLK1 knockdown exerts a greater chemotherapeutic effect on neuroblastoma, cells were incubated at
10 nM RA after being transfected with SiRNA-DLK1. Neuronal differentiation was increased more by a combination of RA and DLK1 knockdown
than by single treatment. Additionally, in order to assess the signal pathway of neuroblastoma differentiation induced by RA and DLK1 knockdown,
treatment with the specific MEK/ERK inhibitors, U0126 and PD 98059, was applied to differentiated neuroblastoma cells. Differentiation induced 
by RA and DLK1 knockdown increased ERK phosphorylation. The MEK/ERK inhibitor U0126 completely inhibited neuronal differentiation induced
by both RA and DLK1 knockdown, whereas PD98059 partially blocked neuronal differentiation. After the withdrawal of inhibitors, cellular differentiation
was fully recovered. This study is, to the best of our knowledge, the first to demonstrate that the specific inhibitors of the MEK/ERK  pathway, 
U0126 and PD98059, exert differential effects on the ERK phosphorylation induced by RA or DLK1 knockdown. Based on the observations of
this study, it can be concluded that a combination of RA and DLK1 knockdown increases neuronal differentiation for the control of the malignant
growth of human neuroblastomas, and also that both MEK1 and MEK2 are required for the differentiation induced by RA and DLK1 knockdown.
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Introduction3)
Neuroblastoma (NB) is the most common malignant disease 
in children and accounts for approximately 15% of all childhood 
cancer death [1]. NB is an extracranial solid tumor originating 
from multipotent neural crest stem cells [2,3]. Significant 
similarities in gene expression profiles have been detected 
between normal neuroblasts and malignant NB [4], thereby 
supporting the notion that malignant NB resemble neural stem 
cells. Unfavorable NB is poorly differentiated [5,6].
Current treatment of NB consists of chemotherapy, surgery, 
and radiation [7]. For many years, it has been recognized that 
the exposure of NB cells to retinoids (all-trans-RA, 13-cis-RA, 
and 9-cis-RA) results in reduced tumor cell proliferation and cell 
differentiation [8]. Retinoids are the biologically active products 
from provitamin A carotenoids including α-carotene, β-carotene, 
and  β-cryptoxanthin [9]. Central cleavage by carotene-15,15’- 
oxygenase is a major pathway leading to vitamin A production 
from provitamin A carotenoids in the body [10]. Retinoic acid 
(RA) is the biologically active form of vitamin A-that is, retinol, 
retinal, and retinyl esters, which are precursors of RA. RA exerts 
its biological role in embryonic development and organogenesis, 
cell proliferation, differentiation, and apoptosis through its 
signaling mediated by the activation of specific nuclear receptors 
[10,11]. Comprehensive studies in vivo and in vitro have provided 
the tumor suppressor functions of vitamin A through its 
metabolites. Retinoids have been employed in clinical trials in 
children with advanced NB. A series of randomized clinical trials 
have shown the benefit of a combination of RA with chemotherapy 
in acute promyelocytic leukemia during induction therapy 
[12,13]. There is no clear roadmap for prioritizing retinoids or 
combination strategies for clinical evaluation. Nonetheless, 
decisions regarding the prioritization of clinical research 
opportunities must be made the basis of the best available 
information, including the results of animal studies and in vitro 
cell studies.
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DLK1 (Drosophila delta-like 1 homologue) is a type I 
transmembrane protein belonging to the epidermal growth factor 
(EGF)-like homeotic gene family, and is homologous to the 
notch/delta/serrate family [14]. DLK1 is also known as 
preadipocyte factor 1 (pref-1), fetal antigen (FA1), pG2, and ZOG 
[14]. DLK1 is expressed extensively in immature cells and down- 
regulated during fetal development [15-17], thereby suggesting 
that DLK1 performs an important role in stem/progenitor cells. 
DLK1 is involved in the differentiation of several cell types, 
including preadipocytes [18], hematopoietic stem cells [19,20] 
and lymphoid progenitors [21,22]. DLK1 expression has also 
been detected in a variety of tumor cells, including NB [23, 24] 
gliomas [25], small-cell lung carcinoma [24], and leukemia [19, 
20]. In a previous study conducted by this researcher, DLK1 
was reported to be expressed preferentially in poorly differentiated 
NB cells, and DLK1 expression was reduced when cells were 
induced to differentiate by RA [26]. Most importantly, the results 
of previous studies have shown that DLK1 may enhance cancer 
cell stemness. Evidence also appears to suggest that DLK1 may 
inhibit tumor cell differentiation and increase tumorigenic 
potential [19,25], although the mechanisms underlying this effect 
remain unclear.
To the extent possible, it is crucial to determine whether the 
signaling pathways perform important functions in preclinical 
models, such as animal or in vitro cell lines. The mitogen- 
activated protein kinase (MAPK) signaling pathways are involved 
in a variety of cellular events, including growth, differentiation, 
and stress responses [27,28]. It has been previously reported that 
ERK (p42/44 MAPK) was phosphorylated in neuronal differentiation 
[28], and DLK1 was involved in multi-signaling pathways, 
including the ERK phosphorylation pathway [26]. Both PD98059 
and U0126 have long been used as specific inhibitors of the ERK 
(p42/44 MAPK) pathway [29-31].
Based on the evidence discussed above, the principal 
hypothesis of this study was that RA and DLK1 perform important 
roles in the differentiation of neuronal cells. A combination of 
RA and DLK1 may induce more significant effects on cell 
differentiation, and thereby block NB tumor cell progression. 
This hypothesis represents a novel perspective on the NB cell 
differentiation induced by RA and DLK1 knockdown. This study 
has the potential not only to elucidate the roles of DLK1 and 
RA in the regulation of NB stem cell phenotype and differentia-
tion, but also to provide mechanistic insights into the progression 
of malignant tumors. The results of this study will benefit the 
prevention and treatment of this deadly childhood cancer.
Materials and Methods
Cell culture and differentiation
SK-N-BE(2)C [BE(2)C] NB cells were cultured in Minimum 
Essential Medium and F12 (1:1) at 37℃ in an atmosphere of 
5% CO2 and 95% air. The media were supplemented with 10% 
fetal bovine serum (v/v). For all experiments, BE(2)C cells were 
cultured to 60-80% confluence. The medium was replaced every 
other day. For viral infection, the cells were infected at 30-50% 
confluence as described previously [32]. In order to induce 
differentiation, BE(2)C cells were treated with various 
concentrations of all-trans-retinoic acid (RA). U0126 and 
PD98059 were purchased from Cell Signaling Technology Inc. 
(Danvers, MA).
RNA interference 
The following siRNA oligonucleotides against human DLK1 
were purchased from Dharmacon (Lafayette, CO): 5’-GCACC 
UGCGUGGAUGAUGAUU-3’ for DLK1 siRNA (05) and 5’- 
GGACGAUGGCCUCUAUGAAUU-3’ for DLK1 siRNA (07). 
The sequence of control siRNA was UAACAAUGAGAGCA 
CGGCUUU. Transfection with siRNAs was performed using 
DharmaFECT (Dharmacon, Lafayette, CO) according to the 
manufacturer’s instruction.
Dr. Tadanori Mayumi (University of Tokyo, Tokyo, Japan) 
kindly provided the lentiviral vectors: pHM5-H1 and CS-CDF- 
EG-PRE-K1f, for the construction of short hairpin RNA (shRNA) 
[33]. Oligonucleotides encoding for both strands of DLK1 
sequences were annealed and inserted into pHM5-H1 between 
BglII and XbaI sites: 5'- GATCCCC GGTGTCCATGAAAGA 
GCTC TTCAAGAGA GAGCTCTTTCATGGACACC  TTTTT 
GGAAA T-3' (sense strand) and 5'- CTAGA TTTCC AAAAA 
GGTGTCCATGAAAGAGCTC TCTCTTGAA GAGCTCTTTC 
ATGGACACC GGG-3' (antisense strand) for ShRNA-DLK1. 
After sequence validation, the cassette containing the H1 promoter 
and a ShRNA-DLK1 sequence was inserted into CS-CDF-EG- 
PRE-K1f between EcoRI and Pst1 sites. The sequence was 
verified further by DNA sequencing. The empty lentiviral vector 
was employed as a negative control.
Western blotting
Cell lysates were prepared on ice in RIPA lysis buffer 
containing 50 mM Tris-Cl at pH 7.5, 150 mM NaCl, 1% Nonidet 
p-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 
1-2 mM PMSF, 1mM NaVO4, and 1mM NaF. The protein 
concentrations were measured using the BCA assay reagents 
(BioRad). 100 μg of whole cell lysate proteins were used for 
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and the separated proteins were transferred to a 
PVDF membrane. After blocking by incubation with 5% BSA 
in Tris-buffered saline for 1 hr at room temperature, the 
membrane was incubated using polyclonal antibody against rabbit 
phospho-extracellular signal-regulated kinase (ERK) (Cell 
Signaling Technology Inc, Danvers, MA). Horse-radish peroxidase- 
conjugated anti-IgG antibody was employed as the secondary 
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Fig. 1. All-trans-retinoic acid (RA) induces neuronal differentiation in 
neuroblastoma and down-regulates stem cell markers (CD133, SOX2, and 
DLK1).  A .  B E ( 2 ) C  c e l l s  w e r e  t r e a t e d  w it h o u t  ( w / o )  o r  w i t h  R A  ( 1 0  n M ,  1 00  nM, 
or 1 μM) for 5 d. β-Tubulin III expression was detected by immunofluorescence. 
Magnification = x100. B. BE(2)C cells were treated without (-) or with 1μM RA (+) 
for 5 d. CD133, SOX2, and DLK1 expression were detected by immunofluorescence. 
Magnification = x100
Fig. 2. Neuronal differentiation was increased by a combination of RA and 
DLK1 knockdown. BE(2)C cells were transfected with DLK1 SiRNA (05), SiRNA (07), 
or a nontargetting SiRNA (Ctrl). Cells were treated without (w/o) or with 10 nM RA 
for 3 d. A. β-Tubulin III expression was detected by immunofluorescence. B. DLK1 
expression  was  detected  by  immunofluorescence.
were bound by enhanced chemiluminescence. Anti β-actin 
(Sigma, St. Louis, MO) was used for a loading control.
Immunofluorescence
BE(2)C Cells were washed with PBS and fixed for 10 min 
with -20º C methanol at room temperature, then washed 3 times 
with PBS. The fixation was removed by aspiration and the cells 
were washed 3 times with PBS for 5 min each. The reaction 
was blocked with 10% horse serum in PBS for 1 hr at room 
temperature. Immunocytochemical analysis was conducted by 
incubating the cells with a 1:50 dilution of anti-DLK1 (R&D 
Systems, Minneapolis, MN) or anti-β-tubulin III (1:70, Sigma, 
St. Louis, MO) in 1% BSA for 2 hrs at room temperature. 
Primary antibody binding was detected with Alexa 594- 
conjugated donkey-anti-mouse (1:500, Invitrogen, Carlsbad, CA) 
or Alexa 488-conjugated goat-anti-rabbit (1:500, Invitrogen, 
Carlsbad, CA) for 1 hr at room temperature. Fluorescence 
microscopy was performed for image detection. 
Results
RA induces neuronal differentiation in NB
Immunofluorescence was employed to evaluate the neuronal 
differentiation induced by RA in NB. RA markedly increased 
neurite growth, a hallmark of neuronal differentiation even at 
a concentration of 10 nM. The neuron-specific marker, β-Tubulin 
III, clearly demonstrated longer neurite growth in the RA-treated 
cells as compared to the non-treated cells. Neurite growth was 
increased in a concentration-dependent manner (Fig. 1A). Further, 
RA reduced the expression of some of the stem cell markers, 
including CD133, SOX2, and DLK1 (Fig. 1B). These observa-
tions corroborate the identification of RA as a true differentiation 
reagent for NB, and DLK1 is a bona fide stem cell/progenitor 
cell marker for immature NB cells.
Neuronal differentiation was increased with a combination of 
RA and DLK1 knockdown
To evaluate the effect of a combination therapy of RA and 
DLK1 knockdown on NB cell differentiation, the cells were 
transfected with two types of SiRNA DLK1 [SiRNA (05) or 
SiRNA (07)] oligonucleotides against human DLK1. The cells 
were then treated for 3 d with 10 nM RA. Both constructs 
inhibited the expression of endogenous DLK1 in BE(2)C cells 
(Fig. 2B). Although DLK1 knockdown spontaneously developed 
neuronal processes, neurite growth was increased dramatically 
by a combination with low concentration of RA treatment as 
revealed by immunofluorescence of the neuron-specific β-tubulin 
III (Fig. 2A). These results clearly indicate that the combination of 
RA and DLK1 knockdown has a more profound chemotherapeutic 
effect due to an induced increase in NB cell differentiation.
MAPK inhibitors block ERK phosphorylation induced by RA
In order to verify the involvement of the MAPK pathway in 
RA-induced NB cell differentiation, the MAPK specific 
inhibitors, U0126 and PD 98059, were administered. 5 μM of 
U0126 completely blocked ERK phosphorylation even at an RA 
treatment concentration of 10 μM. However, PD98059 partially 
blocked ERK phosphorylation at 1 μM or 10 μM of RA 
(Fig. 3).Yuri Kim 279
Fig. 3. MAPK inhibitors block ERK phosphorylation induced by RA. BE(2)C cells 
were treated at various concentrations (0, 1 μM, 10 μM) of RA. Cells were treated 
w it h  M E K /E R K  in h ib it o rs , U 0 1 2 6  (5  μ M ) a n d  P D 9 8 0 5 9  (P D , 5  μ M ) o n t h e  n e x t 
day, and then maintained for 3 d. ERK phosphorylation was analyzed by Western 
Blotting.  β-actin  was  used  as  a  loading  control. 
Fig. 4. MAPK inhibitors, U0126 or PD 98059 (PD) blocks neuronal 
differentiation induced by RA. Cells were treated without (w/o) or with RA (1 nM, 
10 nM) and then treated with 5 μM of U0126 (A) or PD (B) on the next day. The 
cells were m aintained  for 3 d . Cell m orphology was exam ined b y phase contrast 
microscopy.  Magnification = 100x
Fig. 5. MAPK inhibitors, U0126 or PD 98059 (PD) blocks neuronal 
differentiation induced by DLK1 knockdown.  BE(2)C  cells  were  infected  with 
control or ShRNA-DLK1 and then treated with various concentrations (0, 2.5 μM, 
5 μM, 10 μM) of U0126 (A) or PD (B) next day. Cells were maintained for 3 d. 
Cell morphology was examined by phase contrast microscopy. Magnification = 100x
Fig. 6. Neuronal differentiation induced by DLK1 knockdown was recovered 
after withdrawal of MAPK inhibitors. BE(2)C  cells  were  infected  with  control  or 
ShRNA-DLK1. Cells were treated with 5 μM U0126 (A) or PD (B) next d ay an d 
m a i n t a i n e d  f o r  5  d  ( m id d le  p a n e l ) .  A f t e r  3  d a y s  o f  t r e a t m e n t ,  U 0 1 2 6  o r  P D  w a s 
withdrawn and cells were maintained for 2 d. Cell morphology was examined by 
phase  contrast  microscopy.  Magnification = 100x
The MAPK inhibitors, U0126 or PD98059, block RA-induced 
differentiation
To examine the effects of MAPK inhibitors on neuronal 
differentiation, RA was applied to BE(2)C cells at different 
concentrations (0 nM, 1 nM or 10 nM). Using specific inhibitors 
(PD98059 and U0126) of the ERK (p42/44 MAPK) pathway, 
unexpected differential effects of these inhibitors on RA-induced 
neuronal differentiation were observed. This neurite growth was 
completely blocked by U0126 but blocked only partially by 
PD98059 (Fig. 4). This result is consistent with the observed 
inhibition of ERK phophorylation as shown in Fig. 3. These 
findings indicate that the effects of these inhibitors are not 
exclusive, owing to an inhibition of the ERK MAPK pathway, 
and may raise some fundamental implications with regard to the 
inhibitors employed.
The MAPK inhibitors, U0126 or PD98059, block the neuronal 
differentiation induced by DLK1 knockdown.
To evaluate the effect of MAPK inhibitors on the neuronal 
differentiation induced by DLK1 knockdown, BE(2)C cells were 
transfected with ShRNA-DLK1, and the cells were treated with 
various concentrations of U0126 or PD98059. As was observed 
under RA treatment (Fig. 4), the cells were differentiated by 
DLK1 knockdown; however, this differentiation was completely 
blocked by U0126 at all concentrations tested. On the other hand, 
PD98059 partially blocked the neuronal cell differentiation 280 Retinoic Acid, DLK1, and differentiation
induced by DLK1 knockdown (Fig. 5). In order to confirm this 
finding, the cells differentiated by DLK1 knockdown were treated 
with each inhibitor for 3 days, after which the inhibitors were 
withdrawn via exchange with fresh media containing no 
inhibitors. After 2 days of withdrawal of the inhibitor, the 
neuronal differentiation of BE(2)C cells was fully recovered (Fig. 
6) in each of the inhibitor-treated group. Even though U0126 
blocked neuronal differentiation more dramatically than did 
PD98059, neurite growth was recovered in both inhibitor groups 
after the withdrawal of each inhibitor. These results demonstrated 
that the differentiation induced by RA and DLK1 knockdown 
may occur via the same pathway. Additionally, U0126 and 
PD98059 exerted different effects on neuronal differentiation.
Discussion
The present study explored the role of RA and DLK1 
knockdown on the NB cell differentiation. The results from this 
investigation demonstrated that the pretreatment of human 
malignant NB cells with a combination of RA and DLK1 
knockdown induced cell differentiation, thereby controlling 
malignant tumor growth through ERK phosphorylation.
NB cell line is used for this study. NB is the most common 
extracranial solid tumor of childhood, accounting for 15% of 
childhood cancer deaths. The non-differentiated stem cell phenotype 
may potentially be an independent risk factor for NB malignancy. 
Although incremental improvements in outcomes have been 
achieved with conventional chemotherapy agents, particularly 
RA, only one-third of children with NB are expected to survive 
long-term with the current chemotherapeutic interventions. The 
use of RA in NB has become the standard therapy.
As RA is tolerated fairly well as a single-agent, it may also 
function in combination therapy with other reagents. A clinical 
trial has been conducted using a combination of RA and SAHA 
that is the histone deacetylase inhibitor [34]. Another combination 
was explored with a combination of RA and ZD6474, a dual 
small molecule inhibitor of receptors for vascular endothelial 
growth factor (VEGF) and epidermal growth factor (EGF) [35]. 
Despite its powerful chemotherapeutic effect, RA has been 
cautioned by producing toxic effects including chelitis and 
headaches. It has been previously reported that the patients 
receiving combination of RA and bexarotene, a chemotherapeutic 
drug for cutaneous T-cell lymphoma, produced fewer RA- 
associated toxic effects [36]. Combinations of retinoids with 
cytotoxic agents have shown enhanced antitumor efficacy in 
some animal models, including a combination of 9-cis-RA with 
cisplatin [37]. Therefore, a combination of RA therapy with other 
agents would be beneficial to reduce toxicity and increase 
antitumor efficacy. In this study, we demonstrated that the 
combination of RA and knock-down of DLK1, one of stem cell 
gene, enhanced NB cell differentiation (Fig. 2). This result 
provided another possible potential chemotherapeutic strategy for 
this deadly child cancer, NB. Since the proximal 5’ promoter/ 
enhancer region of the DLK1 gene contains retinoic acid receptor 
elements, it would be interesting to characterize the mechanisms 
by which RA affects DLK1 transcription via the RA-dependent 
mechanism. 
Elevated DLK1 expression is also reported in several tumor 
types, particularly neuronal tumors like NB and glioma [38]. 
Nonetheless, the role of DLK1 and its mechanism in tumor 
growth remains to be clearly elucidated. If DLK1 maintains 
tumor cells in a stem cell-like state, the relatively long lifespan 
of stem cells will allow undifferentiated tumor cells to 
accumulate and perpetuate stable genetic and epigenetic changes 
that ultimately result in tumor malignancy. The role of DLK1 
in tumor progression needs to be investigated in further detail. 
In addition, there is a lack of evidence in the literatures 
demonstrating any other chemopreventive agents or dietary 
components that can down-regulate DLK1 expression. Currently, 
further researches on chemopreventive agents or dietary components 
that can affect DLK1 expression are underway in our laboratory.
Very little is known regarding the molecular mechanism and 
signal transduction pathway of DLK1 in cell differentiation. In 
a previously study, DLK1 was proposed to exert a potential 
impact on several membrane-associated signaling pathways that 
facilitate the maintenance or self-renewal of neuronal stem/ 
progenitor cells such as EGFR, FGFR, and Notch, in addition 
to ERK phosphorylation [26]. To further provide the mechanism 
of signaling pathway of RA and DLK1 on NB cell differentiation, 
MAPK inhibitors, U0126 and PD98059, were used. In the present 
study, the phosphorylation of ERK during neuronal differentiation 
was shown to be induced by RA (Fig. 3) and MAPK inhibitors 
blocked neuronal differentiation induced by RA and DLK1 
knockdown (Fig. 4 and 5). U0126 and PD98059 have been 
identified as specific inhibitors for the ERK/MEK1/2 pathway, 
and thus have been employed to study the involvement of the 
MAPK pathway in cellular events including differentiation 
[29,31]. Both U0126 and PD98059 are MEK inhibitors, and both 
are useful in probing the functions of MEK in a variety of 
biological processes, particularly those involving mitogen-activated 
protein kinase (MAP kinase/ERK) activation [39].
The findings of this study demonstrated that the differential 
effects of U0126 and PD98059 on neuronal cell differentiation 
induced by either RA or DLK1 knockdown (Fig. 4 and 5). The 
precise action mechanisms of U0126 and PD98059 as MEK 
inhibitors, and in particular as ERK inhibitors, remain a matter 
of some controversy. It has been reported previously that U0126 
directly inhibits MEK1/2 activity, whereas PD 98059 does not 
directly inhibit MEK1 activity but does inhibit its activation 
(phosphorylation) by Raf-1 [29]. Furthermore, previous studies 
have demonstrated that U0126 inhibits MEK1 and MEK2, and 
PD98059 [29] inhibits MEK1, but only inefficiently inhibits 
MEK2 [40]. However, equilibrium binding studies showed that 
U0126 and PD98059 bind to MEK1 at identical or overlapping 
sites [40]. Dang and Lowik [41] characterized the differential Yuri Kim 281
effects of PD98059 and U0126 on osteogenesis and adipogenesis. 
However, this present study is the first to demonstrate that 
specific inhibitors of the ERK (p42/44 MAPK) pathway, 
PD98059 and U0126, exerted differential effects on the ERK 
phosphorylation induced by RA in NB. Therefore, even though 
there is clearly some overlap in the activities of U0126 and 
PD98059, U0126 evidenced more efficient inhibition than was 
observed with PD98059. This indicates that the neuronal 
differentiation induced by either RA or DLK1 knockdown 
requires the inhibition of both MEK1 and MEK2, as opposed 
to only one of each.
In conclusion, combination therapy is particularly important 
in cancer chemotherapy in regard to safety considerations. The 
findings of this study demonstrated that RA and DLK1 could 
provide a novel therapeutic as well as preventive strategy for 
regulating the differentiation of human malignant NB cells.
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